Obesity, metabolic syndrome, adipocytes and vascular function: A holistic viewpoint

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 1, 2011, Pages 1-10

  Achike, Francis I ^a   To, Nim Hin Peter ^b   Wang, Huidi ^c   Kwan, Chiu Yin ^b  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c BROCK UNIVERSITY   (Canada)

Author keywords

Diabetes mellitus; Metabolic syndrome; Obesity; Perivascular adipose tissue; Vascular reactivity

Indexed keywords

ADIPOCYTOKINE; AGOUTI RELATED PROTEIN; AMPHETAMINE; CATHEPSIN; COCAINE; FIBRONECTIN; GHRELIN; LEPTIN; MATRIX METALLOPROTEINASE; NEUROPEPTIDE Y; PROOPIOMELANOCORTIN;

ADIPOCYTE; ARCUATE NUCLEUS; ATHEROSCLEROSIS; AUTONOMIC NERVOUS SYSTEM FUNCTION; BLOOD VESSEL REACTIVITY; CHRONIC INFLAMMATION; COMORBIDITY; DIABETES MELLITUS; DYSLIPIDEMIA; ENERGY BALANCE; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LEARNING; LIPID STORAGE; METABOLIC SYNDROME X; OBESITY; REVIEW; SEDENTARY LIFESTYLE; VASCULAR ENDOTHELIUM; WAKEFULNESS;

ADIPOCYTES; ANIMALS; BLOOD VESSELS; GASTROINTESTINAL HORMONES; HOLISTIC HEALTH; HUMANS; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; OBESITY; PERCEPTION;

EID: 78650670158     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2010.05460.x     Document Type: Review

References (112)

1. Dorland's Pocket Medical Dictionary. Dorland's Pocket Medical Dictionary, 25th edn. WB Saunders, Philadelphia, 1995; 581.
2. Bray GA. Obesity. In: Fauci AS, Braunwald E, Isselbacher KJ et al. (eds). Harrison's Principles of Internal Medicine, 14th edn. McGraw- Hill, New York, 1998; 454-62.
3. World Health Organization (WHO). Consultation on Obesity. Obesity: Preventing and Managing the Global Epidemic. WHO Technical Report Series 894. WHO, Geneva. 1999.
4. Prentice AM. The emerging epidemic of obesity in developing countries. Int. J. Epidemiol. 2006; 35: 93-9.
5. Eknoyan G. Adolphe Quetelet (1796-1874) - the average man and indices of obesity. Nephrol. Dial. Transplant. 2008; 23: 47-51.
6. Lee CD, Blair SN, Jackson AS. Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men. Am. J. Clin. Nutr. 1999; 69: 373-80.
7. Lean ME. Pathophysiology of obesity. Proc. Nutr. Soc. 2000; 59: 331-6.
8. Christensen R, Bartels EM, Astrup A, Bliddal H. Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: A systematic review and meta-analysis. Ann. Rheum. Dis. 2007; 66: 433-9.
9. Reaven G. Banting Lecture 1988: Role of insulin resistance in human disease. Diabetes 1988; 37: 124-8.
10. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 2003; 108(Suppl. 1): 1541-5.
11. Grundy SM, Brewer B, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-8.
12. Steppan CM, Bailey ST, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-12.
13. Singer G, Granger DN. Inflammatory responses underlying the microvascular dysfunction associated with obesity and insulin resistance. Microcirculation 2007; 14: 375-87.
14. Ravussin E, Bogardus C. Energy balance and weight regulation: Genetics versus environment. Br. J. Nutr. 2000; 83(Suppl. 1): S17-20.
15. Egger G, Swinburn B. An 'ecological' approach to the obesity pandemic. BMJ 1997; 315: 477-80.
16. Halberg N, Wernstedt I, Scherer PE. The adipocyte as an endocrine cell. Endocrinol. Metab. Clin. North Am. 2008; 37: 753-67.
17. Dallman MF. Viewing the ventromedial hypothalamus from the adrenal gland. Am. J. Physiol. 1984; 246: R1-12.
18. Jacobowitz DM, O'Donohue TL. α-Melanocyte stimulating hormone: Immunohistochemical identification and mapping in neurons of rat brian. Proc. Natl Acad. Sci. USA 1978; 75: 6300-4.
19. Cone RD. Anatomy and regulation of the central melanocortin system. Nat. Neurosci. 2005; 8: 571-8.
20. Inui A, Asakawa A, Bowers CY et al. Ghrelin, appetite, and gastric motility: The emerging role of the stomach as an endocrine organ. FASEB J. 2004; 18: 439-56.
21. Dhillo WS. Appetite regulation: An overview. Thyroid 2007; 17: 433-45.
22. Shariat-Madar B, Kolte D, Verlangieri A, Shariat-Madar Z. Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment. Diabetes Metab. Syndr. Obes. 2010; 3: 67-78.
23. Wilding JP, Ajala MO, Lambert PD, Bloom SR. Additive effects of lactation and food restriction to increase hypothalamic neuropeptide Y mRNA in rats. J. Endocrinol. 1997; 152: 365-9.
24. Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B. Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology 1993; 133: 1753-8.
25. Yang L, Scott KA, Hyun J et al. Role of dorsomedial hypothalamic neuropeptide Y in modulating food intake and energy balance. J. Neurosci. 2009; 29: 179-90.
26. Garcia de Yebenes E, Li S, Fournier A, St-Pierre S, Pelletier G. Regulation of proopiomelanocortin gene expression by neuropeptide Y in the rat arcuate nucleus. Brain Res. 1995; 674: 112-6.
27. Wieland HA, Hamilton BS, Drist B, Doods HN. The role of NPY in metabolic homeostasis: Implications for obesity therapy. Invest. Drugs 2000; 9: 1327-46.
28. Balasubramaniam A. Neuropeptide Y (NPY) family of hormones. Progress in the development of receptor selective agonists and antagonists. Curr. Pharm. Des. 2003; 9: 1165-75.
29. Kalra SP, Kalra PS. To subjugate NPY is to improve the quality of life and live longer. Peptides 2007; 28: 413-8.
30. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-60.
31. 1 receptor pathway. Diabetes 2001; 50: 227-32.
32. Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Wakabayashi I. Central effect of ghrelin, an endogenous growth hormone secretagogue, on hypothalamic peptide gene expression. Endocrinology 2000; 141: 4797-800.
33. Cowley MA, Smith RG, Diano S et al. The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis. Neuron 2003; 37: 649-61.
34. Tschöp M, Wawarta R, Riepl RL et al. Post-prandial decrease of circulating human ghrelin levels. J. Endocrinol. Invest. 2001; 24: RC19-21.
35. Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50: 707-9.
36. Neary NM, Small CJ, Wren AM et al. Ghrelin increases energy intake in cancer patients with impaired appetite: Acute, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 2004; 89: 2832-6.
37. Yasuda T, Masaki T, Kakuma T, Yoshimatsu H. Centrally administered ghrelin suppresses sympathetic nerve activity in brown adipose tissue of rats. Neurosci. Lett. 2003; 349: 75-8.
38. Atcha Z, Chen WS, Ong AB et al. Cognitive enhancing effects of ghrelin receptor agonists. Psychopharmacology 2009; 206: 415-27.
39. Jerlhag E, Egecioglu E, Dickson SL, Andersson M, Svensson L, Engel JA. Ghrelin stimulates locomotor activity and accumbal dopamine-overflow via central cholinergic systems in mice: Implications for its involvement in brain reward. Addict. Biol. 2004; 11: 45-54.
40. Jerlhag E, Egecioglu E, Dickson SL, Douhan A, Svensson L, Engel JA. Ghrelin administration into tegmental areas stimulates locomotor activity and increases extracellular concentration of dopamine in the nucleus accumbens. Addict. Biol. 2007; 12: 6-16.
41. Zhang JV, Ren PG, Avsian-Kretchmer O et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005; 310: 996-9.
42. Berna MJ, Tapia JA, Sancho V, Jensen RT. Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential. Curr. Opin. Pharmacol. 2007; 7: 583-92.
43. Green DE. New therapies for diabetes. Clin. Cornerstone 2007; 8: 58-63.
44. Tian L, Gao J, Hao J et al. Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology 2010; 15: 3049-60.
45. Katra B, Klupa T, Skupien J et al. Dipeptidyl peptidase-IV inhibitors are efficient adjunct therapy in HNF1A maturity-onset diabetes of the young patients: Report of two cases. Diabetes Technol. Ther. 2010; 12: 313-6.
46. Cowley MA, Smart JL, Rubinstein M et al. Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 2001; 411: 480-4.
47. Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 1996; 334: 292-5.
48. Mantzoros CS, Flier JS. Leptin as a therapeutic agent: Trials and tribulations. J. Clin. Ednocrinol. Metab. 2000; 85: 4033-9. [Editorial].
49. Zelissen PM, Stenlof K, Lean ME et al. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: A randomized, placebo-controlled trial. Diabetes Obes. Metab. 2005; 7: 755-61.
50. Kadowaki T. PPAR gamma agonist and antagonist. Folia Pharmacologica Japonica 2001; 118: 321-6.
51. Ukkola O, Santaniemi M. Adiponectin: A link between excess adiposity and associated comorbidities? J. Mol. Med. 2002; 80: 696-702.
52. Coppola A, Marfella R, Coppola L et al. Effect of weight loss on coronary circulation and adiponectin levels in obese women. Int. J. Cardiol. 2009; 134: 414-6.
53. Fumeron F, Aubert R, Siddiq A, et al. Adiponectin gene polymorphisms and adiponectin levels are independently associated with the development of hyperglycemia during a 3-year period: the epidemiologic data on the insulin resistance syndrome prospective study. Diabetes 2004; 53: 1150-7.
54. Fang X, Sweeney G. Mechanisms regulating energy metabolism by adiponectin in obesity and diabetes. Biochem. Soc. Trans. 2006; 34: 798-801.
55. Bonnard C, Durand A, Vidal H, Rieusset J. Changes in adiponectin, its receptors and AMPK activity in tissues of diet-induced diabetic mice. Diabetes Metab. 2008; 34: 52-61.
56. Díez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur. J. Endocrinol. 2003; 148: 293-300.
57. Wong NL, Achike FI. Gender discrimination in the influence of hyperglycemia and hyperosmolarity on rat aortic tissue responses to insulin. Regul. Pept. 2010; 163: 113-9.
58. Wolf G. Adiponectin: A regulator of energy homeostasis. Nutr. Rev. 2003; 61: 290-2.
59. Teske JA, Billington CJ, Kotz CM. Hypocretin/orexin and energy expenditure. Acta Physiol. 2010; 198: 303-12.
60. 2+ channel-activated slow afterhyperpolarization in thalamic paraventricular nucleus and other thalamic midline neurons. J. Neurophysiol. 2009; 101: 2741-50.
61. Hoang QV, Bajic D, Yanagisawa M, Nakajima S, Nakajima Y. Effects of orexin (hypocretin) on GIRK channels. J. Neurophysiol. 2003; 90: 693-702.
62. Tsuneki H, Wada T, Sasaoka T. Role of orexin in the regulation of glucose homeostasis. Acta Physiol. 2010; 198: 335-48.
63. Hall JE. Pathophysiology of obesity hypertension. Curr. Hypertens. Rep. 2000; 2: 139-47.
64. Hall JE, Brands MW, Hildebrandt DA, Kuo J, Fitzgerald S. Role of sympathetic nervous system and neuropeptides in obesity hypertension. Braz. J. Med. Biol. Res. 2000; 33: 605-18.
65. Teran-Garcia M, Bouchard C. Genetics of the metabolic syndrome. Appl. Physiol. Nutr. Metab. 2007; 32: 89-114.
66. Ruetsch O, Viala A, Bardou H, Martin P, Vacheron MN. Psychotropic drugs induced weight gain: A review of the literature concerning epidemiological data, mechanisms and management. Encephale 2005; 31: 507-16.
67. Antras J, Hilliou F, Redziniak G, Pairault J. Decreased biosynthesis of actin and cellular fibronectin during adipose conversion of 3T3-F442A cells. Reorganization of the cytoarchitecture and extracellular matrix fibronectin. Biol. Cell 1989; 66: 247-54.
68. Taleb S, Cancello R, Clément K, Lacasa D. Cathepsin s promotes human preadipocyte differentiation: Possible involvement of fibronectin degradation. Endocrinology 2006; 147: 4950-9.
69. Brekken RA, Sage EH. SPARC, a matricellular protein: At the crossroads of cell-matrix communication. Matrix Biol. 2001; 19: 816-27.
70. Tartare-Deckert S, Chavey C, Monthouel MN, Gautier N, Van ObberghenE. The matricellular protein SPARC/osteonectin as a newly identified factor up-regulated in obesity. J. Biol. Chem. 2001; 276: 22231-7.
71. Bouloumié A, Sengenès C, Portolan G, Galitzky J, Lafontan M. Adipocyte produces matrix metalloproteinases 2 and 9: Involvement in adipose differentiation. Diabetes 2001; 50: 2080-6.
72. Chavey C, Mari B, Monthouel MN et al. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J. Biol. Chem. 2003; 278: 11888-96.
73. Kralisch S, Bluher M, Tonjes A et al. Tissue inhibitor of metalloproteinase-1 predicts adiposity in humans. Eur. J. Endocrinol. 2007; 156: 257-61.
74. Lin Y, Rajala MW, Berger JP, Moller DE, Barzilai N, Scherer PE. Hyperglycemia-induced production of acute phase reactants in adipose tissue. J. Biol. Chem. 2001; 276: 42077-83.
75. Berg AH, Lin Y, Lisanti MP, Scherer PE. Adipocyte differentiation induces dynamic changes in NF-kappaB expression and activity. Am. J. Physiol. Endocrinol. Metab. 2004; 287: E1178-88.
76. Tsuchida A, Yamauchi T, Takekawa S et al. Peroxisome proliferator-activated receptor (PPAR) alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue. Comparison of activation of PPARalpha, PPARgamma, and their combination. Diabetes 2005; 54: 3358-70.
77. Alleva DG, Johnson EB, Lio FM, Boehme SA, Conlon PJ, Crowe PD. Regulation of murine macrophage proinflammatory and anti-inflammatory cytokines by ligands for peroxisome proliferator-activated receptor-gamma: Counter-regulatory activity by IFN-gamma. J. Leukoc. Biol. 2002; 71: 677-85.
78. Unger RH. Lipotoxic diseases. Annu. Rev. Med. 2002; 53: 319-36.
79. Rahmouni K, Correia ML, Haynes WG, Mark AL. Obesity-associated hypertension: New insights into mechanisms. Hypertension 2005; 45: 9-14.
80. Knudson JD, Dincer UD, Dick GM et al. Leptin resistance extends to the coronary vasculature in prediabetic dogs and provides a protective adaptation against endothelial dysfunction. Am. J. Physiol. Heart Circ. Physiol. 2005; 289: H1038-46.
81. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE et al. Serum resistin (FIZZ3) protein is increased in obese humans. J. Clin. Endocrinol. Metab. 2003; 88: 5452-5.
82. McTernan CL, McTernan PG, Harte AL, Levick PL, Barnett AH, Kumar S. Resistin, central obesity, and Type 2 diabetes. Lancet 2002; 359: 46-7.
83. Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem. Biophys. Res. Commun. 2005; 334: 1092-101.
84. Eringa EC, Bakker W, Smulders YM, Serné EH, Yudkin JS, Stehouwer CD. Regulation of vascular function and insulin sensitivity by adipose tissue: Focus on perivascular adipose tissue. Microcirculation 2007; 14: 389-402.
85. Valsamakis G, McTernan PG, Chetty R et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 2004; 53: 430-4.
86. Nigro J, Osman N, Dart AM, Little PJ. Insulin resistance and atherosclerosis. Endocr. Rev. 2006; 27: 242-59.
87. Ritchie SA, Ewart MA, Perry CG, Connell JM, Salt IP. The role of insulin and the adipocytokines in regulation of vascular endothelial function. Clin. Sci. 2004; 107: 519-32.
88. Van Guilder GP, Hoetzer GL, Smith DT et al. Endothelial t-PA release is impaired in overweight and obese adults but can be improved with regular aerobic exercise. Am. J. Physiol. Endocrinol. Metab. 2005; 289: E807-13.
89. Dave GS, Kalia K. Hyperglycemia induced oxidative stress in Type-1 and Type-2 diabetic patients with and without nephropathy. Cell. Mol. Biol. 2007; 53: 68-78.
90. Lastra G, Manrique C. The expanding role of oxidative stress, renin angiotensin system, and beta-cell dysfunction in the cardiometabolic syndrome and Type 2 diabetes mellitus. Antioxid. Redox Signal. 2007; 9: 943-54.
91. Kaneto H, Nakatani Y, Kawamori D, Miyatsuka T, Matsuoka TA. Involvement of oxidative stress and the JNK pathway in glucose toxicity. Rev. Diabet. Stud. 2004; 1: 165-74.
92. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: The role of endothelial dysfunction. Clin. Sci. 2005; 109: 143-59.
93. Ferder L, Inserra F, Martínez-Maldonado M. Inflammation and the metabolic syndrome. Role of angiotensin II and oxidative stress. Curr. Hypertens. Rep. 2006; 8: 191-8.
94. Chin LC, Achike FI, Mustafa MR. Hydrogen peroxide modulates angiotensin II-induced contraction of mesenteric arteries from streptozotocin-induced diabetic rats. Vasc. Pharmacol. 2007; 46: 223-8.
95. Ajay M, Achike FI, Mustafa MR. Modulation of vascular reactivity in normal, hypertensive and diabetic rat aortae by a non-antioxidant flavonoid. Pharmacol. Res. 2007; 55: 385-91.
96. Fardoun RZ. The use of vitamin e in Type 2 diabetes mellitus. Clin. Exp. Hypertens. 2007; 29: 135-48.
97. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 875-80.
98. Henrichot E, Juge-Aubry CE, Pernin A et al. Production of chemokines by perivascular adipose tissue: A role in the pathogenesis of atherosclerosis? Arterioscler. Thromb. Vasc. Biol. 2005; 25: 2594-9.
99. Gao YJ. Dual modulation of vascular function by perivascular adipose tissue and its potential correlation with adiposity/lipoatrophy-related vascular function. Curr. Pharm. Des. 2007; 13: 2185-92.
100. Fernandez-Alfonso MS. Regulation of vascular tone: The fat connection. Hypertension 2004; 44: 255-6.
101. Soltis EE, Cassis LA. Influence of perivascular adipose tissue on rat aortic muscle reasponsiveness. Clin. Exp. Hypertens. 1991; 275: 681-92.
102. Lohn M, Dubrovska G, Lauterbach B, Luft FC, Gollasch M, Sharma AM. Periadventitial fat releases a vascular relaxing factor. FASEB J. 2002; 16: 1057-63.
103. Gao YJ, Lu C, Su LY, Sharma AM, Lee RMKW. Modulation of vascular function by perivascular adipose tissue: The role of endothelium and hydrogen peroxide. Br. J. Pharmacol. 2007; 151: 323-31.
104. Lee RM, Lu C, Su LY, Gao YJ. Endothelium-dependent relaxation factor released by pervascular adipose tissue. J. Hypertens. 2009; 27: 782-90.
105. Chua CB, Achike FI, Kwan CY. Anatomical regional differences in aortic tissue reactivity: The role of perivascular adipose tissue in normal and diabetic rats. In: Final programme of the 16th World Congress of Basic and Clinical Pharmacology, 17-23 July 2010, Copenhagen, Denmark. 2010; Abstract no. 194.
106. Lee RM, Ding L, Lu C, Su LY, Gao YL. Alteration of perivascular adipose tissue function in angiotensin II-induced hypertension. Can. J. Physiol. Pharmacol. 2009; 87: 944-53.
107. Gao YJ, Takamori K, Su LY et al. Perivascular adipose tissue promotes vasoconstriction: The role of superoxide anion. Cardiovasc. Res. 2006; 71: 363-73.
108. Kwan CY, Hsieh WT, To PNH, Wang HD. New perspectives on vascular wall signaling. Role of perivascular adipocytes and fibrobalsts. Acta Pharmacol. Sin. 2010; 31: 1022-5.
109. Fruhbeck G. Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes 1999; 48: 903-8.
110. Lembo G, Vecchione C, Fratta L et al. Leptin induces direct vasodilatation through distinct endothelial mechanisms. Diabetes 2000; 49: 293-7.
111. Engeli S, Schling P, Gorzelniak K et al. The adipose tissue rennin-angiotensin-aldosterone system: Role in the metabolic syndrome? J. Biochem. Cell Biol. 2003; 35: 807-25.
112. de Groot AA, van Zwieten PA, Peters SL. Involvement of reactive oxygen species in angiotensin II-induced vasoconstriction. J. Cardiovasc. Pharmacol. 2004; 43: 154-9.